- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02616666
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE)
December 4, 2023 updated by: University of Liverpool
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)
A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
A longitudinal, open labelled, pragmatic randomized 104 week multicentre trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Study Type
Interventional
Enrollment (Actual)
632
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alton, United Kingdom
- Research Site
-
Altrincham, United Kingdom
- Research Site
-
Birmingham, United Kingdom
- Research Site, Alum Rock
-
Blackburn, United Kingdom
- Research Site
-
Cambridge, United Kingdom
- Research Site
-
Cirencester, United Kingdom
- Research Site
-
Cockermouth, United Kingdom
- Research Site
-
Colchester, United Kingdom
- Research Site
-
Colindale, United Kingdom
- Research Site
-
Dudley, United Kingdom
- Research Site
-
Edmonton, United Kingdom
- Research Site
-
Fareham, United Kingdom
- Research Site
-
Fleet, United Kingdom
- Research Site
-
Gravesend, United Kingdom
- Research Site
-
Hull, United Kingdom
- Research Site
-
Kineton, United Kingdom
- Research Site, Market Square
-
Kings Norton, United Kingdom
- Research Site
-
Langport, United Kingdom
- Research Site
-
Leamington Spa, United Kingdom
- Research Site
-
Liphook, United Kingdom
- Research Site
-
Liverpool, United Kingdom
- Research Site
-
London, United Kingdom
- Research Site
-
London, United Kingdom, N8
- Research Site
-
Maryport, United Kingdom
- Research Site
-
Morriston, United Kingdom
- Research Site
-
Newport, United Kingdom
- Research Site
-
Oxford, United Kingdom
- Research Site
-
Oxford, United Kingdom, OX2
- Research Site
-
Petersfield, United Kingdom
- Research Site
-
Rowlands Castle, United Kingdom
- Research Site
-
Stansted, United Kingdom
- Research Site
-
Stratford-upon-Avon, United Kingdom
- Research Site
-
Torquay, United Kingdom
- Research Site
-
Wallsend, United Kingdom
- Research Site
-
Waterlooville, United Kingdom
- Research Site
-
Wembley, United Kingdom
- Research Site
-
-
Angus
-
Forfar, Angus, United Kingdom
- Research Site
-
-
Avon
-
Yate, Avon, United Kingdom
- Research Site
-
-
Berkshire
-
Bracknell, Berkshire, United Kingdom
- Research Site
-
Reading, Berkshire, United Kingdom
- Research Site
-
Wokingham, Berkshire, United Kingdom
- Research Site
-
-
Bridgend
-
Maesteg, Bridgend, United Kingdom
- Research Site
-
-
Bristol
-
Chew Stoke, Bristol, United Kingdom
- Research Site
-
Yate, Bristol, United Kingdom
- Research Site
-
-
Bucks
-
Iver, Bucks, United Kingdom
- Research Site
-
-
Caerphilly
-
Blackwood, Caerphilly, United Kingdom
- Research Site
-
-
Carrickfergus
-
Greenisland, Carrickfergus, United Kingdom
- Research Site
-
Whitehead, Carrickfergus, United Kingdom
- Research Site
-
-
Cheshire
-
Macclesfield, Cheshire, United Kingdom
- Research Site
-
-
County Durham
-
Crook, County Durham, United Kingdom
- Research Site
-
-
Denbighshire
-
Denbigh, Denbighshire, United Kingdom
- Research Site
-
-
Devon
-
Exeter, Devon, United Kingdom
- Research Site
-
-
East Yorkshire
-
Hull, East Yorkshire, United Kingdom
- Research Site
-
-
Essex
-
Romford, Essex, United Kingdom
- Research Site
-
-
Exeter
-
Pinhoe, Exeter, United Kingdom
- Research Site
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, United Kingdom
- Research Site
-
-
Greater Manchester
-
Trafford, Greater Manchester, United Kingdom
- Research Site
-
Worsley, Greater Manchester, United Kingdom
- Research Site
-
-
Hampshire
-
Alton, Hampshire, United Kingdom
- Research Site
-
Farnborough, Hampshire, United Kingdom
- Research Site
-
Gosport, Hampshire, United Kingdom
- Research Site
-
Havant, Hampshire, United Kingdom
- Research Site
-
Romsey, Hampshire, United Kingdom
- Research Site
-
Southampton, Hampshire, United Kingdom
- Research Site
-
Waterlooville, Hampshire, United Kingdom
- Research Site
-
Winchester, Hampshire, United Kingdom
- Research Site
-
-
Hants
-
Southampton, Hants, United Kingdom
- Research Site
-
-
Herefordshire
-
Leominster, Herefordshire, United Kingdom
- Research Site
-
-
Highland
-
Fortrose, Highland, United Kingdom
- Research Site
-
-
Kent
-
Beckenham, Kent, United Kingdom
- Research Site
-
Canterbury, Kent, United Kingdom
- Research Site
-
Faversham, Kent, United Kingdom
- Research Site
-
Gravesend, Kent, United Kingdom
- Research Site
-
Rainham, Kent, United Kingdom
- Research Site
-
-
Lancashire
-
Barnoldswick, Lancashire, United Kingdom
- Research Site
-
Blackburn, Lancashire, United Kingdom
- Research Site
-
Darwen, Lancashire, United Kingdom
- Research Site
-
Lancaster, Lancashire, United Kingdom
- Research Site
-
Nelson, Lancashire, United Kingdom
- Research Site
-
Thornton-Cleveleys, Lancashire, United Kingdom
- Research Site
-
-
Lancs
-
Thornton-Cleveleys, Lancs, United Kingdom
- Research Site
-
-
Leicestershire
-
Loughborough, Leicestershire, United Kingdom
- Research Site
-
-
London
-
Brockley, London, United Kingdom
- Research Site
-
Rotherhithe, London, United Kingdom
- Research Site
-
Streatham, London, United Kingdom
- Research Site
-
-
Manchester
-
Trafford, Manchester, United Kingdom
- Research Site
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom
- Research Site
-
Wirral, Merseyside, United Kingdom
- Research Site
-
-
Middlesex
-
Wembley, Middlesex, United Kingdom
- Research Site
-
-
Neath Port Talbot
-
Glyncorrwg, Neath Port Talbot, United Kingdom
- Research Site
-
-
Norfolk
-
Swaffham, Norfolk, United Kingdom
- Research Site
-
-
North Somerset
-
Clevedon, North Somerset, United Kingdom
- Research Site
-
-
North Yorkshire
-
Pickering, North Yorkshire, United Kingdom
- Research Site
-
Ripon, North Yorkshire, United Kingdom
- Research Site
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom
- Research Site
-
-
Notts
-
Nottingham, Notts, United Kingdom
- Research Site
-
-
Oxfordshire
-
Bicester, Oxfordshire, United Kingdom
- Research Site
-
Carterton, Oxfordshire, United Kingdom
- Research Site
-
Oxford, Oxfordshire, United Kingdom
- Research Site
-
Wantage, Oxfordshire, United Kingdom
- Research Site
-
Witney, Oxfordshire, United Kingdom
- Research Site
-
-
Oxon
-
Oxford, Oxon, United Kingdom
- Research Site
-
-
Pembrokeshire
-
Milford Haven, Pembrokeshire, United Kingdom
- Research Site
-
-
Rhondda Cynon Taf
-
Pontypridd, Rhondda Cynon Taf, United Kingdom
- Research Site
-
-
Rhondda Cynon Taff
-
Tonypandy, Rhondda Cynon Taff, United Kingdom
- Research Site
-
-
Shropshire
-
Telford, Shropshire, United Kingdom
- Research Site
-
-
Somerset
-
Axbridge, Somerset, United Kingdom
- Research Site
-
-
South Ayrshire
-
Ayr, South Ayrshire, United Kingdom
- Research Site
-
-
South Yorkshire
-
Worsborough, South Yorkshire, United Kingdom
- Research Site
-
-
Suffolk
-
Bury St Edmunds, Suffolk, United Kingdom
- Research Site
-
-
Surrey
-
Camberley, Surrey, United Kingdom
- Research Site
-
Guildford, Surrey, United Kingdom
- Research Site
-
London, Surrey, United Kingdom
- Research Site
-
-
Swansea
-
Killay, Swansea, United Kingdom
- Research Site
-
-
Vale Of Glamorgan
-
Barry, Vale Of Glamorgan, United Kingdom
- Research Site
-
-
Warks
-
Nuneaton, Warks, United Kingdom
- Research Site
-
-
Warwickshire
-
Alcester, Warwickshire, United Kingdom
- Research Site
-
Atherstone, Warwickshire, United Kingdom
- Research Site
-
Bidford-on-Avon, Warwickshire, United Kingdom
- Research Site
-
Nuneaton, Warwickshire, United Kingdom
- Research Site
-
Stratford-upon-Avon, Warwickshire, United Kingdom
- Research Site
-
Warwick, Warwickshire, United Kingdom
- Research Site
-
-
West Midlands
-
Walsall, West Midlands, United Kingdom
- Research Site
-
Wolverhampton, West Midlands, United Kingdom
- Research Site
-
-
West Sussex
-
Crawley, West Sussex, United Kingdom
- Research Site
-
-
Wiltshire
-
Swindon, Wiltshire, United Kingdom
- Research Site
-
-
Worcestershire
-
Droitwich, Worcestershire, United Kingdom
- Research Site
-
Kidderminster, Worcestershire, United Kingdom
- Research Site
-
Malvern, Worcestershire, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
For inclusion in the study patients should fulfil the following criteria at the time of screening:
- Provision of informed consent prior to any study specific procedures
- Females and males aged ≥18 years up to ≤ 75 years
- Diagnosed with Type 2 Diabetes Mellitus.
- Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c > 6.5%.
- Ability to read and write as judged by the investigator.
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- Previous enrolment or randomization in the present study
- Age > 75 years
- Pregnancy/active breast feeding at the time of inclusion
- Known moderate to severe renal impairment (eGFR<60ml/min).
- Participation in an interventional clinical trial ≤ 3 months before enrolment.
- Unsuitable to participate on mental health grounds, as judged by the investigator.
- Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin.
- Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin 10 mg
Patients will be randomized to receive either dapagliflozin or SOC.
As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs).
Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
|
The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator).
Dapagliflozin will be given in combination with metformin.
Other Names:
|
Active Comparator: Standard of Care (SOC)
Patients will be randomized to receive either dapagliflozin or SOC.
As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs).
Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
|
The comparator arm consists of SOC.
The SOC arm can be sulphonylurea (SU) or non-SU treatments.
SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin.
The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy.
Other SGLT-2 inhibitors are excluded.
All these treatments are approved in the UK for use in this patient population.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.
Time Frame: Assessment of outcome measure will be made at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
|
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint including HbA1c reduction vs. baseline (≥ 0.5%), weight loss vs. baseline (≥ 2 Kg), no reported severe or documented hypoglycaemic events since randomization, and no switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC),at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
|
Assessment of outcome measure will be made at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c success (HbA1c reduction vs. baseline ≥ 0.5%) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame: From randomization to 104 weeks of follow up.
|
HbA1c reduction
|
From randomization to 104 weeks of follow up.
|
Weight loss success (weight vs. baseline ≥ 2 Kg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame: closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
|
Weight Loss success
|
closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
|
Severe or documented hypoglycaemic events up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
Time Frame: Up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
|
Documented Hypoglycaemic events
|
Up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
|
To assess differences between dapagliflozin and SOC in the proportion of patients not switching from or adding to the treatment to which the patient was randomized (
Time Frame: up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
Switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC) up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
To assess differences between dapagliflozin and SOC in the change from baseline in HbA1
Time Frame: HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closet to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closet to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
Time Frame: At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
|
At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
Time Frame: At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
|
At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the patients health related quality of life as measured by SF35v2 at 6, 12, 18 and 24 months
Time Frame: At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the patients health related quality of life, specifically physical, functioning, role functioning and vitality domains as measured by SF35v2 at 6, 12, 18 and 24 months
|
At 6, 12, 18 and 24 months
|
To assess differences between dapagliflozin and SOC in the proportion of patients needing antihypertensive escalation (dose up titration, switch and add-on strategies),
Time Frame: up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
Antihypertensive initiation or escalation (dose up titration, switch and add-on strategies), up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
To assess differences between dapagliflozin and SOC in the proportion of patients with diabetic complications:
Time Frame: up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
Proportion of patients with the following diabetic complications:
|
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg)
Time Frame: Closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
|
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
Closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
|
To assess differences between dapagliflozin and SOC in the change from baseline in eGFR
Time Frame: closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
eGFR (ml/min) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
|
To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization
Time Frame: up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
Hospitalizations, contacts due to hypoglycaemic events, needing insulin treatment, complications and unscheduled GP visits, up to 52 weeks following randomization and separately, up to 104 weeks following randomization
|
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jesús Medina, PhD, AstraZeneca
- Principal Investigator: John Wilding, MBChB, DM, Universtiy of Liverpool, University Hospital, Aintree, Longmoor Lane, Liverpool, L9 7AL, UK
- Study Director: Susan Beatty, MSc, Clinical Practice Research Datalink
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 25, 2016
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
July 31, 2024
Study Registration Dates
First Submitted
November 17, 2015
First Submitted That Met QC Criteria
November 25, 2015
First Posted (Estimated)
November 30, 2015
Study Record Updates
Last Update Posted (Estimated)
December 5, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1690R00009
- 2015-001873-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on Dapagliflozin
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaRecruitingLiver CirrhosisSpain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil